William Tansey

Research from the lab of Bill Tansey and other collaborators tested protein inhibitors called WINi against a panel of cancer cells and found that they have strong action against blood cancers and synergize with an FDA-approved cancer drug. Read More

William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth. Read More

MYC is a family of three related proteins that are overexpressed in cancer and which contribute to an estimated 100,000 cancer deaths annually in the United States. Understanding how MYC works could lead to the development of new drugs that can effectively block MYC and stop many cancers in their tracks. Read More

Basic research underway at Vanderbilt University Medical Center is raising hopes that one day it will be possible to reverse memory loss in people with Alzheimer’s disease and stop a major driver of cancer in its tracks. Read More

How epigenetic regulation of gene transcription forms new memories and triggers cancerous growth is the subject of the next Vanderbilt Discovery Lecture on Oct. 26. Read More

Leading cancer investigators from several prominent universities and laboratories will headline the 2017 Vanderbilt-Ingram Cancer Center Annual Scientific Retreat, to be held Thursday, May 4. Read More

William Tansey, Ph.D., professor of Cell Development and Biology and Ingram Professor of Cancer Research, has been awarded a two-year, $250,000 grant from Alex’s Lemonade Stand Foundation (ALSF) to study malignant rhabdoid tumors (MRTs). Read More

Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks. Read More